Scholars Central

Conference abstractPublished 6 Oct 2014

Fluoroquinolones: Anti-HCV drugs of the future?

Authors: Syed H Ali

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

HCV is responsible for about 200 million infections worldwide. The current therapy against HCV has numerous adverse effects, and is too costly for developing countries. In the present study, we assessed the efficacy of fluoroquinolone group of drugs against HCV helicase enzyme NS3, using in vitro and in silico approaches. For in vitro analysis, purified NS3 protein was used in helicase assays to assess the inhibitory effect of fluoroquinolones. Drugs that showed strong inhibition of NS3 were docked onto the NS3 protein using computer simulation. In vitro experimental analysis showed that several fluoroquinolones strongly inhibited the helicase activity of NS3. Docking analysis established that each of these drugs interacted strongly with different amino acids in the active site of NS3.This study will provide the basis for designing new fluoroquinolones derivatives that have the combined properties of pre-existing drugs, and hence a higher potency against HCV.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Antivirals & Antiretrovirals.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Antivirals & Antiretrovirals
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Syed H Ali”